… have replaced vitamin K antagonists as the preferred class of OACs… comparative effectiveness
and safety of dabigatran, rivaroxaban and apixaban in a nationwide population of patients …

… compared to other DOACs and vitamin K antagonists (… changes in the German population,
the number of patients with AF is … In routine clinical practice, a patient is more likely to withdraw …

… Conclusion In patients with nonvalvular atrial fibrillation or … [56] In routine practice, efforts
should be made to establish a … regarding extrapolations of comparative effectiveness. However, …

… based on how the drug is being used in clinical practice, its effectiveness, safety, and
associated costs. The availability of a RWE meta-analysis provides a good opportunity to evaluate …

… Current practice guidelines recommend a vitamin-K antagonist (… apixaban may be a reasonable
alternative to VKA in patients … from 92 hospitals performing TAVI procedures in Germany …

… compared relative efficacy and safety of edoxaban vs. other … , and apixaban compared
with vitamin K antagonists. The … to learn about the current use of NOACs in routine practice. …

… However, despite these statements, our results also showed that clinicians still prefer
warfarin over DOAC for AF patients with BPHV in real-world practice; approximately 80% of …

… trial comparing edoxaban with vitamin K antagonists in patients with prevalent or incident
atrial fibrillation … The primary efficacy outcome was a composite of adverse events consisting of …

… %) included patients with atrial fibrillation treated with DOAC for … age for patients treated
with apixaban and rivaroxaban … , Italian and German studies compared with the patients in the …

… , apixaban), vitamin K antagonists (VKA), such as warfarin and acenocoumarol are still the
most widely used oral anticoagulants for the treatment of nonvalvular atrial fibrillation … practice. …